



**FRENCH AGENCY FOR FOOD, ENVIRONNEMENTAL AND OCCUPATIONAL
HEALTH SAFETY**

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS

**14 RUE CLAUDE BOURGELAT – PARC D’ACTIVITES DE LA GRANDE MARCHE
JAVENE – CS 70611 – 35306 FOUGERES**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

**BIOCLINDAVET 110 mg/mL
Oral solution for cats and dogs**

Bioclindavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

PRODUCT SUMMARY

EU procedure number	FR/V/0482/001/DC
Name, strength and pharmaceutical form	Bioclindavet 110 mg/ml oral solution for cats and dogs
Applicant	AXIENCE 14 RUE SCANDICCI, TOUR ESSOR 93500 PANTIN FRANCE
Active substance(s)	Clindamycin
ATC vetcode	QJ01FF01
Target species	Cats, Dogs
Indication for use	For oral use. Recommended dose: Cats: Infected wounds, abscesses: 11 mg of clindamycin per kg of body weight (i.e. 0.1 mL of veterinary medicinal product / kg bw) per 24 hours for 7 to 10 days. Dogs: - Infected wounds, abscesses and oral cavity/dental infections: 11 mg clindamycin per kg of bodyweight (i.e. 0.1 mL of veterinary medicinal product / kg bw) per 24 hours for 7 to 10 days. The duration of treatment depends on the decision of the responsible veterinarian. - Treatment of bone infections (osteomyelitis): 11 mg clindamycin per kg of body weight (i.e. 0.1 mL of veterinary medicinal product / kg bw) per 12 hours for a period of 28 days minimum. The treatment should be discontinued if no therapeutic effect is observed in the first 14 days. The minimum volume that can be accurately administered is 0.02 ml, corresponding to an animal weighing a minimum of 0.4 kg at the dose of 5.5 mg/kg per administration. Increments of 0.02 ml only are accurate.

Bioclandavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

Bioclandavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

SUMMARY OF ASSESSMENT

Legal basis of original application*	Hybrid application of Regulation (EU) 2019/6 application in accordance with Article 19(1) of Regulation (EC) 2019/6 as amended.
Reference product (RP)	ANTIROBE GOUTTES 25 mg/mL ORAL SOLUTION
Marketing authorisation holder	ZOETIS FRANCE
Marketing authorisation number	FR/V/5318391 0/1990
EU procedure number	
Date of authorisation	04/05/1990
Proprietary data have been submitted for the following part of the dossier	Change in strength
Date of completion of the original decentralised procedure	01/10/2025
Concerned Member States for original procedure	AT, BE, BG, CY, DE, ES, IE, IT, NL, RO, SK

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the observed reactions are indicated in the SPC.

The VMP is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

Bioclandavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

A. Product description

The VMP contains clindamycin hydrochloride (110 mg/mL) and the excipients sorbitol, liquid (non-crystallising), glycerol, propylene glycol and purified water, saccharine sodium, sucralose, caramel flavor, vanillin, hydrochloric acid, concentrated and sodium hydroxide.

The container/closure system is an amber glass bottle closed with white polypropylene child-resistant closure and Low-Density Polyethylene (LDPE) syringe adaptor.

Details of the device with which the VMP will be administered are provided, as applicable.

The choice of the formulation is justified.

The VMP is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the VMP have been presented in accordance with the relevant European guidelines.

C. Production and control of starting materials

The active substance is clindamycin hydrochloride, an established substance described in the European Pharmacopeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this VMP.

D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable.

Bioclandavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits have been justified and are considered appropriate to adequately control the quality of the VMP.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability tests

A re-test period is mentioned on the certificates of suitability for the active substance.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life when stored under the approved conditions.

G. Other information

Not applicable.

3. SAFETY DOCUMENTATION (safety and residues tests)

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of safety tests are not required.

The safety aspects of this VMP are identical to the reference VMP.

Warnings and precautions as listed on the product literature are the similar to those of the reference VMP and are adequate to ensure safety of the product to users / the environment / consumers.

A. Safety tests

Pharmacological studies

See Part 4.A.

Bioclinidavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

Toxicological studies

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of safety tests are not required.

Other studies

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of safety tests are not required.

Observations in humans

The applicant has provided general information in humans related to the active ingredient.

Development of resistance and related risk in humans

The applicant provided sufficient bibliographical data in support of the application to meet the current legal requirements. No guidance is currently available on how to assess the risk of development of resistance and related risks in humans. See also part 4.A.

Adequate warnings and precautions appear on the product literature.

User safety

The applicant has provided a user safety assessment in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

This is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated. According to the reflection paper on the interpretation of article 18(7) and since a VMP, which have been authorised after 1 October 2005, with the same active substance indicated for use in the same target species when administered at the same or a higher total dose as the proposed generic VMP, has been found, an Environmental Risk Assessment is not required.

Bioclandavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

Warnings and precautions as listed on the product literature are the same as those of the reference VMP and are adequate to ensure safety of the environment.

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, efficacy studies are not required.

The efficacy claims for this VMP are equivalent to those of the reference VMP.

A. Pre-Clinical Studies

Pharmacology

The applicant has conducted two *in vivo* bioequivalence studies in the target species, dogs and cats. Bioequivalence with a reference VMP has been demonstrated.

Development of resistance and related risk in animals

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6, information about the level of resistance, as known from bibliographic data, shall be provided. The applicant provided a review of bibliographical data on antimicrobial resistance for pathogens of clinical relevance for the claimed indication in the target animal species.

Adequate warnings and precautions appear on the product literature.

Dose determination and confirmation

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, dose determination and confirmation studies are not required.

Tolerance in the target species of animals

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, tolerance studies are not required.

The safety aspects of this VMP are identical to the reference VMP.

Warnings and precautions as listed on the product literature are the same as those of the reference VMP and are adequate to ensure safety of the product to target species of animals.

Bioclindavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

B. Clinical trials

As this is a hybrid application according to Article 19 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, clinical trials are not required.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.

Bioclindavet 110 mg/ml oral solution for cats and dogs	FR/V/0482/001/DC
AXIENCE	DCP
Publicly available assessment report	

POST-AUTHORISATION PROCEDURES

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the VMP. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes, which have been made after the original procedure, which are important for the quality, safety or efficacy of the VMP :

None